David Renas News Today

Investegate announcements from ObsEva SA, ObsEva Announces Management Change

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - October 29, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing

ObsEva SA: ObsEva Provides Business Outlook for 2021 GENEVA, Switzerland and BOSTON, MA (February 10, 2021) - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021. "We made significant progress across all aspects of the company in 2020, most significantly preparing Yselty for uterine fibroids for re...

for Uterine Fibroids ObsEva is developing Yselty®, an oral GnRH receptor antagonist with the potential to treat more women thanks to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) recent validation of the marketing authorization application (MAA), a major milestone toward making Yselty® available in the E.U., the Company will continue to work clos...

ObsEva Provides Business Outlook for 2021   GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021. “We made significant progress across all aspects of the company in 2020, most significantly preparing Yselty® for uterine fibroids for r...